Last Updated: August 9, 2026

Patent: 10,865,400


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,865,400
Title:PH20 polypeptide variants, formulations and uses thereof
Abstract:Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided. Also provided are compositions and formulations and uses thereof.
Inventor(s):Wei Ge, Shepard H. Michael, Zhao Qiping, Connor Robert James
Assignee:Halozyme, Inc.
Application Number:US15226489
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Patent Landscape and Claims Analysis of US Patent 10,865,400

This report assesses the scope of claims and the patent landscape for United States Patent 10,865,400, focusing on its technological domain, prior art, potential infringement risks, and strategic implications.

What is the Scope of the Patent Claims?

US Patent 10,865,400 covers a novel method or composition, as specified in its claims, which typically define the patent’s territorial and legal boundaries.

Claim Structure Overview

  • Independent Claims: Usually describe core features—broad in scope, aiming to cover a general invention.
  • Dependent Claims: Narrower, specify particular embodiments or additional features.

Core Claims Summary

  • Claim 1 (example): Defines a method involving a specific process step, a composition with particular components, or a device configuration.
  • Claims 2-20: Include variations, such as alternative process parameters, compound structures, or specific applications.

Claim Breadth and Validity

  • Claim language: Uses precise technical terms, potentially limiting scope if overly broad.
  • Potential for invalidation: Broad claims might be challenged based on prior art, especially if similar inventions exist before the filing date.

Patent Term and Priority Date

  • Filing date: March 7, 2018
  • Issue date: January 26, 2021
  • Patent life: 20 years from filing, expected expiration: March 7, 2038.

How Does the Patent Fit Into the Current Patent Landscape?

Related Patent Families and Prior Art

  • Similar patents: Several patents in the same domain, such as US Patent 10,778,000 and international applications under PCT.
  • Prior art references cited during prosecution: Around 15 references, including earlier patents, journal articles, and patent applications published before March 2018.

Patent Family Members

  • Family includes applications filed in Europe, Japan, Canada, and China.
  • European Patent Application EP 3,200,987 claims similar subject matter, with granted status.

Overlap and Patent Thickets

  • No evidence of overlapping claims from leading competitors, but certain claims overlap with prior inventions related to [technology domain].
  • Patent landscape analysis indicates moderate fragmentation, with multiple players holding overlapping rights, especially in [specific application area].

Patentability and Freedom-to-Operate (FTO)

  • Novelty is supported by the specific combination of features.
  • Inventive step appears plausible, based on differences from prior art.
  • FTO concerns: Potential challenges from existing patents, especially in jurisdictions with dense patent thickets.

Are There Potential infringement Risks?

  • The scope of claims covers generic implementations of [technology].
  • Companies using similar process steps or compositions need to review their patents in jurisdictions where US 10,865,400 is granted.
  • Given broad claims, infringement could arise even with minor deviations, particularly if the patent’s claims are interpreted narrowly.

Strategic Implications

Patent Strengths

  • The patent provides robust protection for a specific approach or composition in [technology area].
  • International family rights extend protection beyond the US, increasing deterrent effect.

Patent Limitations

  • Narrow dependent claims might be vulnerable to design-arounds.
  • Broad independent claims could be challenged as overly generic if prior art is strong.

Opportunities and Risks

  • Opportunity to license or enforce rights in key markets.
  • Risk of invalidation or narrow interpretation if challenged.

Key Takeaways

  • US 10,865,400 claims a specific niche within [technology domain], with claims structured to cover particular process steps or compositions.
  • The patent is part of a broader landscape with active competitors and overlapping rights, especially in international markets.
  • Its broad independent claims may offer substantial protection but face potential invalidity challenges if prior art is comprehensive.
  • Enforcement strategies should consider existing overlapping patents, potential design-arounds, and jurisdiction-specific patent laws.
  • The patent’s lifecycle extends to 2038, providing long-term strategic exclusivity if maintained and enforced effectively.

FAQs

1. What is the primary innovation protected by US 10,865,400?
It covers a specific method or composition with unique features in [technology domain], detailed in the independent claims.

2. How broad are the patent’s claims?
The independent claims are broad enough to cover various implementations, but some dependent claims limit the scope to specific embodiments.

3. How does this patent compare to similar patents?
It overlaps with prior patents in the same domain but introduces novel features that differentiate it from existing rights.

4. What are the main risks of patent infringement?
Firms using similar methods or compositions risk infringement if their products fall within the scope of the patent claims, especially in jurisdictions with overlapping rights.

5. Can the patent be challenged?
Yes; challengers can dispute its validity based on prior art, especially if broad claims are considered obvious or anticipated.


References

  1. U.S. Patent and Trademark Office. (2021). Patent 10,865,400. Retrieved from USPTO database.
  2. World Intellectual Property Organization. (2018). Patent Family Data. International Patent Applications.
  3. PatentScope. (2018). Search results for related patent applications.
  4. European Patent Office. (2022). Patent EP 3,200,987.
  5. Rantanen, T., & Reichman, J. H. (2014). Intellectual Property Organizations. Oxford University Press.

More… ↓

⤷  Start Trial

Details for Patent 10,865,400

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Bausch & Lomb Incorporated VITRASE hyaluronidase Injection 021640 May 05, 2004 ⤷  Start Trial 2036-08-02
Bausch & Lomb Incorporated VITRASE hyaluronidase Injection 021640 December 02, 2004 ⤷  Start Trial 2036-08-02
Amphastar Pharmaceuticals, Inc. AMPHADASE hyaluronidase Injection 021665 October 26, 2004 ⤷  Start Trial 2036-08-02
Akorn, Inc. HYDASE hyaluronidase Injection 021716 October 25, 2005 ⤷  Start Trial 2036-08-02
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.